Clinical

Articles

Data from a phase 2 clinical trial with pembrolizumab and cetuximab yielded promising clinical activity in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Pembrolizumab Plus Cetuximab Demonstrate Promising Clinical Activity for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Videos

Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.

Eric J. Sherman, MD, on Agents for Treating RET Fusion–Positive Thyroid Cancer

Eric J. Sherman, MD, examines the phase 3 COSMIC-311 trial with cabozantinib in radioiodine-refractory differentiated thyroid cancer.

Eric J. Sherman, MD, on the Efficacy of Cabozantinib in Refractory Differentiated Thyroid Cancer

Eric J. Sherman, MD, highlights trends he observed with immunotherapy in the head and neck cancer space.

Eric J. Sherman, MD, on Immunotherapy Trends in Head and Neck Cancer

Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.

Eric J. Sherman, MD, Discusses the Use of Adjuvant Capecitabine in Nasopharynx Cancer

Patients with long-term oropharyngeal cancer were surveyed regarding factors leading to severe effects on voice and speech. 

Risk Factors of Adverse Voice and Speech Effects of Oropharyngeal Cancer Identified Through Patient Reported Surveys

Results of the phase 3 JUPITER-02 trial presented at ASCO 2021 support the use of toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma. 

PFS Boost Observed in Metastatic Nasopharyngeal Carcinoma Treated With Frontline Toripalimab/Chemotherapy Combo

A new treatment arm of a phase 2 trial examining PDS0101 plus pembrolizumab in patients with HPV-related head and neck cancers will be opened to patients with immune checkpoint inhibitor–pretreated disease.

VERSATILE-002 Trial to Enroll Previously Treated HPV+ HNSCC Per Protocol Amendment 

Penpulimab may be a future treatment option for patients with nasopharyngeal cancer in the third line of therapy dependent on success of a recent biologics license application submitted to the FDA. 

Application for PD-1 Inhibitor Penpulimab in Nasopharyngeal Cancer Submitted to FDA 

BeiGene’s press release details the positive progression-free survival data observed with the combination of tislelizumab plus chemotherapy compared with placebo plus chemotherapy for patients with recurrent or metastatic nasopharyngeal cancer.

Head & Neck Cancer | Topics